๐๏ธ Verified NIH Record โข Updated 2025-06-10
Tirzepatide for Obesity and Meth Use Disorder (NCT06745128)
Tirzepatide for Individuals With Comorbid Obesity and Methamphetamine Use Disorder
๐ต Active, Not Recruiting Phase2 ๐ Investigational Drug / Biologic Sponsor: University of Texas Southwestern Medical Center
๐ฉบ Plain-English Summary (8th-Grade Level)
This is an open-label pilot study to evaluate the feasibility and preliminary efficacy of using tirzepatide when prescribed for its United States (US) Food and Drug Administration (FDA)-approved weight-related indication in individuals with comorbid methamphetamine use disorder.
Who can join: Review the eligibility criteria below.
Location: UT Southwestern Medical Center โ Dallas, Texas
Age range: 18 Years to 65 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (1 Sites)
- UT Southwestern Medical Center โ Dallas, Texas
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Obesity
- Reducing Weight and Elevated Stress Levels Using Educational and Behavioral Tools โ Tampa, Florida
- SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity โ Tucson, Arizona
- Piloting a Patient Navigator Program for Weight Loss โ Philadelphia, Pennsylvania
- Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2) โ Mesa, Arizona
- Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects โ Orlando, Florida
- Intestinal Metabolic Reprogramming as a Key Mechanism of Gastric Bypass in Humans โ Pittsburgh, Pennsylvania
Explore by condition: All Obesity clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.